{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT04475588: Phase 2 Interventional Completed Acute Respiratory Distress Syndrome
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:camalprin alfa [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:erepdekinra [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:umizortamig [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:delpacibart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:eciskafusp alfa [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:calotatug ginistinag [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:tabirafusp alfa tedromer [INN]
Source URL:
Class:
PROTEIN